Localized CD47 blockade enhances immunotherapy for murine melanoma

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

Targeting Immunotherapy to the Tumor Microenvironment

(2017) Michael Dougan et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease

(2017) Novalia Pishesha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer

(2016) Isabel Van Audenhove et al.   EBioMedicine

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy

(2015) Jonathan T. Sockolosky et al.   ADVANCED DRUG DELIVERY REVIEWS

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis

(2015) Chia Chi M. Ho et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Noninvasive imaging of immune responses

(2015) Mohammad Rashidian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts

(2012) Alexandre P.A. Theocharides et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IAP inhibitors enhance co-stimulation to promote tumor immunity

(2010) Michael Dougan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology